Last reviewed 2026-05-22 · How we verify

Rimegepant 75 MG (rimegepant-75-mg)

Pfizer Inc. · preclinical active Under review Quality 25/100

Rimegepant 75 MG (generic name: rimegepant-75-mg) is a CGRP receptor antagonist (gepant) drug developed by Pfizer Inc.. It is currently in preclinical development.

Rimegepant selectively antagonizes the calcitonin gene-related peptide (CGRP) receptor to block migraine pain signaling.

Rimegepant 75 MG is a small molecule that acts as an antagonist to the calcitonin gene-related peptide type 1 receptor. It is used to treat various types of migraines, including episodic migraine, menstrual migraine, migraine with aura, and migraine without aura.

Likelihood of approval

5% vs 5% industry baseline

If approved by FDA: likely 2036–2040

Steps remaining: Phase 1 → Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Low

Why this estimate

Baseline preclinical → approval rate +5.0pp
Industry-wide preclinical drugs reach approval ~5% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
Big-pharma sponsor +3.0pp
Pfizer Inc. is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2036–2040	—
EMA	EU	2037–2041	+0.7 yr
MHRA	GB	2037–2041	+0.7 yr
Health Canada	CA	2037–2042	+0.9 yr
TGA	AU	2037–2042	+1.2 yr
PMDA	JP	2037–2042	+1.5 yr
NMPA	CN	2038–2043	+2.3 yr
MFDS	KR	2037–2042	+1.4 yr
CDSCO	IN	2037–2043	+1.8 yr
ANVISA	BR	2038–2043	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	rimegepant-75-mg
Sponsor	Pfizer Inc.
Drug class	CGRP receptor antagonist (gepant)
Target	Calcitonin gene-related peptide (CGRP) receptor
Therapeutic area	Neuroscience
Phase	preclinical

Mechanism of action

Rimegepant works by blocking the CGRP receptor, a G-protein coupled receptor found on trigeminal sensory neurons and other pain-processing tissues. CGRP is a neuropeptide released during migraine attacks that triggers vasodilation, neuroinflammation, and pain signal amplification. By antagonizing this receptor, rimegepant interrupts the cascade of events that leads to migraine headache, photophobia, phonophobia, and associated symptoms. The drug crosses the blood-brain barrier as a small molecule, allowing it to act on both central and peripheral CGRP receptors. This mechanism differs from monoclonal antibody CGRP antagonists (like erenumab) by offering rapid oral absorption and faster symptom relief, making it suitable for acute migraine treatment rather than prevention alone.

Approved indications

No approved indications tracked.

Pipeline indications

Acute treatment of migraine with or without aura — Phase 3
Preventive treatment of episodic migraine — Phase 4
Preventive treatment of menstrual migraine — Phase 3
Acute treatment of migraine in pediatric subjects — Phase 3
Acute treatment of chronic rhinosinusitis with and without nasal polyps — Phase 3

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Rimegepant 75 MG CI brief — competitive landscape report
Rimegepant 75 MG updates RSS · CI watch RSS
Pfizer Inc. portfolio CI

Frequently asked questions about Rimegepant 75 MG

What is Rimegepant 75 MG?

Rimegepant 75 MG (rimegepant-75-mg) is a CGRP receptor antagonist (gepant) drug developed by Pfizer Inc..

How does Rimegepant 75 MG work?

Rimegepant selectively antagonizes the calcitonin gene-related peptide (CGRP) receptor to block migraine pain signaling.

Who makes Rimegepant 75 MG?

Rimegepant 75 MG is developed by Pfizer Inc. (see full Pfizer Inc. pipeline at /company/pfizer).

What is the generic name of Rimegepant 75 MG?

rimegepant-75-mg is the generic (nonproprietary) name of Rimegepant 75 MG.

What drug class is Rimegepant 75 MG in?

Rimegepant 75 MG belongs to the CGRP receptor antagonist (gepant) class. See all CGRP receptor antagonist (gepant) drugs at /class/cgrp-receptor-antagonist-gepant.

What development phase is Rimegepant 75 MG in?

Rimegepant 75 MG is in preclinical.

What does Rimegepant 75 MG target?

Rimegepant 75 MG targets Calcitonin gene-related peptide (CGRP) receptor and is a CGRP receptor antagonist (gepant).

Drug class: All CGRP receptor antagonist (gepant) drugs
Target: All drugs targeting Calcitonin gene-related peptide (CGRP) receptor
Manufacturer: Pfizer Inc. — full pipeline
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing